The biologic role of ITGAV specifically in ccRCC has not yet been well characterized; however, Crona et al. identified an intronic variant of ITGAV that leads to overexpression and is associated with decreased OS among TKI-treated patients [43]. The gene discussed is ITGAV; the disease is nonpapillary renal cell carcinoma.